Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 222
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +25%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07570966	Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	withdrawn	Phase 1 / Phase 2	0	Novartis PharmaceuticalsINDUSTRY	0	Jun 22, 2026	clinicaltrials
NCT07025512	177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia	withdrawn	Phase 2	0	M.D. Anderson Cancer CenterOTHER	0	May 8, 2026